Gabather

0.04 SEK

-11.21 %

Less than 1K followers

GABA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-11.21 %

-16.30 %

+42.86 %

+38.69 %

+16.56 %

+6.15 %

-96.11 %

-97.48 %

-99.10 %

Gabather is a pharmaceutical company whose business focus is to develop drug candidates for the treatment of neurological diseases. The focus is particularly on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.

Market cap

23.2M SEK

Turnover

382.5K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

29.5

2026

Interim report Q1'26

26.6

2026

General meeting '26

31.8

2026

Interim report Q2'26

All

Press releases

3rd party

ShowingAll content types

Press releaseyesterday

Västra Hamnen Market Focus: Gabather comments on the new patent application

Press release3/19/2026, 9:00 AM

Västra Hamnen Market Focus: Gabather: Key shareholders show support

Third party research3/3/2026, 2:29 PM

Gabather: Any day now - VH Corp

* Exercise of warrants and a directed share issue extends runway * Phase II clinical trial expected to start very soon * After dilution, our fair value amounts to SEK 0.06 per share Gabather’s Q4 report showed lower-than-expected costs, primarily due...

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release3/3/2026, 2:00 PM

Västra Hamnen Market Focus: Gabather: Any day now

Third party research3/3/2026, 12:50 PM

Gabather presents Q4 2025 - VH Corp

CEO Michael-Robin Witt answers questions about the Q4 report and discusses other recent news with Västra Hamnen's analyst Jacob Murat.

Press release3/3/2026, 12:30 PM

Västra Hamnen Market Focus: Gabather presents Q4 2025

Third party research12/1/2025, 1:57 PM

Gabather: Eager to start the TOTEMS study - VH Corp

* A TOTEMS study article published in Frontiers in Psychiatry * The exercise of TO 7 warrants provides some financial relief * We keep our fair value of SEK 0.092 per share Gabather's reported figures in its recent Q3 report were close to our estimates...

Press release12/1/2025, 1:45 PM

Västra Hamnen Market Focus: Gabather: Eager to start the TOTEMS study

Third party research9/1/2025, 10:05 AM

Gabather: TOTEMS-study delayed, not derailed - VH Corp

* Issues with clinical test material delays TOTEMS-study * New chairman elected at the AGM * We keep our fair value of SEK 0.092 per share Before releasing its Q2 2025 report, Gabather announced that the TOTEMS-study would be delayed due to issues with...

Press release9/1/2025, 10:00 AM

Västra Hamnen Market Focus: Gabather: TOTEMS-study delayed, not derailed

Third party research6/19/2025, 8:27 AM

Gabather: High potential in specific modulation - VH Corp

• Novel therapeutics addressing the GABAA receptor system in the CNS • An exploratory phase II study in schizophrenia is ongoing • We initiate coverage with a fair value of SEK 0.092 per share Gabather is a drug developer in precision medicine targeting...

Third party research3/6/2025, 8:55 AM

Gabather: Redefining Cognitive Disorder Treatment - Analyst Group

Gabather AB (“Gabather” or “the Company”) is advancing GT-002, a first-in-class GABAA-modulator, through Phase II clinical trials, targeting cognitive dysfunction. With a fully funded schizophrenia Phase II trial and a planned expansion into Phase II...

Regulatory press release1/13/2025, 7:30 AM

Gabather AB appoints Pareto Securities AB to act as a liquidity provider for the Company's share

Regulatory press release4/10/2024, 11:00 AM

Gabather AB: Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002

Press release3/18/2024, 7:30 AM

Gabather AB: Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders

Press release3/7/2024, 8:02 AM

Gabather AB: Gabather reports initial positive results from the EEG/fMRI target engagement study

Regulatory press release12/22/2023, 2:03 PM

Gabather AB receives initial EEG data analysis from the GT-002 target engagement study

Regulatory press release12/14/2023, 8:16 AM

Gabather AB initiates discussions with specialist doctors and researchers at Karolinska Institutet for the design of a study in individuals at risk of developing frontotemporal dementia (FTD)

Regulatory press release12/11/2023, 12:23 PM

Gabather AB broadens the scope of EEG data analysis generated during the target engagement study by partnering with MINDIG

Regulatory press release10/12/2023, 12:00 PM

Gabather AB: Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.